BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 18414782)

  • 1. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
    Guénard F; Labrie Y; Ouellette G; Joly Beauparlant C; Simard J; ; Durocher F
    J Hum Genet; 2008; 53(7):579. PubMed ID: 18414782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
    Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function.
    De Nicolo A; Tancredi M; Lombardi G; Flemma CC; Barbuti S; Di Cristofano C; Sobhian B; Bevilacqua G; Drapkin R; Caligo MA
    Clin Cancer Res; 2008 Jul; 14(14):4672-80. PubMed ID: 18628483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
    Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
    Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.
    García MJ; Fernández V; Osorio A; Barroso A; Fernández F; Urioste M; Benítez J
    Carcinogenesis; 2009 Nov; 30(11):1898-902. PubMed ID: 19737859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
    Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
    Alter BP; Best AF
    Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphic variations in the FANCA gene in high-risk non-BRCA1/2 breast cancer individuals from the French Canadian population.
    Litim N; Labrie Y; Desjardins S; Ouellette G; Plourde K; Belleau P; ; Durocher F
    Mol Oncol; 2013 Feb; 7(1):85-100. PubMed ID: 23021409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of BRIP1 Variants among Korean Patients with BRCA1/2 Mutation-Negative High-Risk Breast Cancer.
    Kim H; Cho DY; Choi DH; Jung GH; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Gil WH; Kim SW
    Cancer Res Treat; 2016 Jul; 48(3):955-61. PubMed ID: 26790966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Mutational Analysis of the BRCA1-Associated DNA Helicase and Tumor-Suppressor FANCJ/BACH1/BRIP1.
    Calvo JA; Fritchman B; Hernandez D; Persky NS; Johannessen CM; Piccioni F; Kelch BA; Cantor SB
    Mol Cancer Res; 2021 Jun; 19(6):1015-1025. PubMed ID: 33619228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
    J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1.
    Cantor SB; Guillemette S
    Future Oncol; 2011 Feb; 7(2):253-61. PubMed ID: 21345144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features.
    Barroso E; Pita G; Arias JI; Menendez P; Zamora P; Blanco M; Benitez J; Ribas G
    Breast Cancer Res Treat; 2009 Dec; 118(3):655-60. PubMed ID: 19536649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.
    Seal S; Thompson D; Renwick A; Elliott A; Kelly P; Barfoot R; Chagtai T; Jayatilake H; Ahmed M; Spanova K; North B; McGuffog L; Evans DG; Eccles D; ; Easton DF; Stratton MR; Rahman N
    Nat Genet; 2006 Nov; 38(11):1239-41. PubMed ID: 17033622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families.
    Catucci I; Milgrom R; Kushnir A; Laitman Y; Paluch-Shimon S; Volorio S; Ficarazzi F; Bernard L; Radice P; Friedman E; Peterlongo P
    Fam Cancer; 2012 Sep; 11(3):483-91. PubMed ID: 22692731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy.
    Eelen G; Vanden Bempt I; Verlinden L; Drijkoningen M; Smeets A; Neven P; Christiaens MR; Marchal K; Bouillon R; Verstuyf A
    Oncogene; 2008 Jul; 27(30):4233-41. PubMed ID: 18345034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rare
    Moyer CL; Ivanovich J; Gillespie JL; Doberstein R; Radke MR; Richardson ME; Kaufmann SH; Swisher EM; Goodfellow PJ
    Cancer Res; 2020 Feb; 80(4):857-867. PubMed ID: 31822495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FANCJ/MutLalpha interaction is required for correction of the cross-link response in FA-J cells.
    Peng M; Litman R; Xie J; Sharma S; Brosh RM; Cantor SB
    EMBO J; 2007 Jul; 26(13):3238-49. PubMed ID: 17581638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BACH1 Ser919Pro variant and breast cancer risk.
    Vahteristo P; Yliannala K; Tamminen A; Eerola H; Blomqvist C; Nevanlinna H
    BMC Cancer; 2006 Jan; 6():19. PubMed ID: 16430786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.